Spero Therapeutics to Present at Cantor’s Global Healthcare 2023 Investor Conference Sep 20, 2023 04:05PM
Spero Therapeutics (SPRO) PT Slashed to $5 at Cantor Fitzgerald, Analyst Maintains "Overweight" Rating May 17, 2022 06:13AM
Spero Therapeutics (SPRO) Reiterated at Overweight by Cantor Fitzgerald, SPR206 Results Support Further Development, Expect Upward Earnings Revisions and Multiple Expansion Feb 16, 2022 09:54AM
Spero Therapeutics (SPRO) Announces Pricing of Common Stock and Series D Convertible Preferred Stock Sep 11, 2020 06:55AM
Spero Therapeutics Announces Pricing of Securities Offering Sep 11, 2020 06:54AM


Sep 11, 2020 06:54AM Spero Therapeutics Announces Pricing of Securities Offering
Sep 9, 2020 04:34PM Spero Therapeutics (SPRO) Announces Proposed 8M Share Common Offering
Sep 9, 2020 04:33PM Spero Therapeutics Announces Proposed Public Offering
Sep 9, 2020 04:33PM Spero Therapeutics Announces Proposed Public Offering
May 21, 2020 07:21AM Companies with NDRs 5/21
May 14, 2020 07:17AM Companies with NDRs 5/14
Jul 16, 2019 09:39AM Cantor Fitzgerald Reiterates Overweight Rating on Spero Therapeutics (SPRO)
Jul 13, 2018 05:47AM Spero Therapeutics (SPRO) Prices 3.78M Share Offering at $12.50/Sh
Jul 12, 2018 08:10PM Spero Therapeutics Announces Pricing of Securities Offering
Jul 9, 2018 04:11PM Spero Therapeutics (SPRO) Commences 4.5M Common Stock Offering
Jul 9, 2018 04:10PM Spero Therapeutics Announces Proposed Offering of Common Stock
May 23, 2018 10:08AM Spero Therapeutics (SPRO) Data Underscores Platform is Underappreciated - Cantor Fitzgerald
Feb 8, 2018 04:07PM Cantor Fitzgerald Starts Spero Therapeutics (SPRO) at Overweight